Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) Gross Margin (2016 - 2026)

Iradimed has reported Gross Margin over the past 14 years, most recently at 76.5% for Q1 2026.

  • Quarterly Gross Margin rose 43.0% to 76.5% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 76.84% through Mar 2026, down 8.0% year-over-year, with the annual reading at 76.75% for FY2025, 19.0% down from the prior year.
  • Gross Margin was 76.5% for Q1 2026 at Iradimed, up from 75.06% in the prior quarter.
  • Over five years, Gross Margin peaked at 79.71% in Q2 2022 and troughed at 75.06% in Q4 2025.
  • The 5-year median for Gross Margin is 76.5% (2026), against an average of 76.9%.
  • Year-over-year, Gross Margin soared 497bps in 2022 and then crashed -416bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 75.49% in 2022, then increased by 2bps to 76.86% in 2023, then fell by -1bps to 76.13% in 2024, then decreased by -1bps to 75.06% in 2025, then rose by 2bps to 76.5% in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Gross Margin are 76.5% (Q1 2026), 75.06% (Q4 2025), and 77.8% (Q3 2025).